- New Agreement Extends Drug Discovery and Development
Collaboration Between the Companies
ALBANY, New York, April 23, 2013 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) announced today that it has entered into a new five-year
service agreement with Ono Pharmaceutical Company, Ltd., (TSE:
4528), a pharmaceutical company headquartered in Osaka, Japan. Under the terms of the
agreement, AMRI may provide a range of services from early drug
discovery to cGMP manufacturing.
(Logo:
http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)
The two companies have already agreed to medicinal chemistry
projects within the new framework to collaborate on additional
hit-to-lead and lead optimization for two new molecules, with the
work to take place at AMRI's medicinal chemistry laboratories in
Albany, N.Y.
An early adopter of the AMRI SMARTSOURCING™ concept, Ono has
been utilizing AMRI's integrated global facilities and capabilities
for projects ranging from early drug discovery, including
high-throughput screening (HTS), biology support and computer-aided
drug discovery (CADD), to multiple medicinal chemistry programs and
a variety of drug development and cGMP programs.
Thomas E. D'Ambra, Ph.D., Chairman, President and CEO of AMRI
said, "We are pleased to extend and broaden our service agreement
with Ono. During the past few years, Ono has become a very
important client for AMRI and we would like to acknowledge the
deepening relationship between our companies. Our project
management teams and the scientists on all the Ono projects, from
Singapore to the United States, enjoy working with our
counterparts at Ono and they are a valuable customer and
partner."
Louis Garguilo, Vice President of
Business Development, said, "SMARTSOURCING™ is an industry leading
movement to strategic decision making and the true measurement of
results and success in drug discovery, development and
manufacturing. Over the years, our relationship with Ono has grown
based on this type of value-added collaboration. We are also happy
to announce this expanding relationship in conjunction with the
2013 Biotechnology Industry Organization (BIO) International
Convention in Chicago, at the
one-year anniversary of our re-branding launch of AMRI
SMARTSOURCING™ at this very show last year in Boston."
Kazuhito Kawabata, Ph.D., Member
of the Board of Directors, Executive Officer and Executive
Director, Discovery and Research of Ono, said, "We appreciate
AMRI's integrated capabilities and global reach, and believe that
they are the partner of choice to mutually work toward the best
decisions and outcomes for many of our projects. We look forward to
continuing our relationship across the drug discovery and
development areas."
About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract
research and manufacturing organization offering customers fully
integrated drug discovery, development, and manufacturing services
for over 21 years. AMRI has demonstrated its adaptability as the
pharmaceutical and biotechnology industries have undergone
tremendous change in response to regulatory and market challenges.
This experience, a track record of success and locations in
the United States, Europe and Asia now provides our customers with
SMARTSOURCING™, a full range of value-added opportunities providing
customers informed decision-making, enhanced efficiency and more
successful outcomes at all stages of the pipeline. AMRI has also
successfully partnered R&D programs and is actively seeking to
out-license its remaining programs for further development. For
more information, please visit us at www.amriglobal.com.
